BBNX vs MMED
BBNX: Beta Bionics is a medical device company developing automated insulin delivery systems to simplify diabetes management. MMED: MiniMed is a diabetes care technology company specializing in automated insulin delivery pumps, continuous glucose monitors, and smart insulin pens for global Type 1 and Type 2 diabetes management.
Side-by-side fundamentals
| Metric | BBNX | MMED | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $16.31 | $16.33 | |
| Market cap as of 2026-07-23 | $780M | $4.6B | |
| Net margin as of 2026-07-23 | -60.3% | -10.7% | MMED higher |
| Gross margin as of 2026-07-23 | +57.1% | +54.2% | BBNX higher |
| Operating margin as of 2026-07-23 | -70.1% | -6.1% | MMED higher |
| ROE as of 2026-07-23 | -23.0% | -9.2% | MMED higher |
| ROA as of 2026-07-23 | -20.5% | -7.2% | MMED higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +56.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +189.1% | +12.1% | BBNX higher |
| Beta as of 2026-07-23 | 0.50 | -0.10 | |
| 1-year return as of 2026-07-22 close | +23.2% | -11.7% | BBNX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.